Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. It develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and bispecific fusion format for the development of novel dual-action antibodies. The company develops ADC-1013, an immunostimulatory antibody, which is in Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial for tumor-directed treatment of metastatic cancer. Its drug candidates in preclinical development stage include ATOR-1017, an immunostimulatory antibody that binds to the costimulatory receptor 4-1BB (CD137) in tumor-specific T cells; ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer; and ATOR-1144, a bispecific antibody for treating solid tumors and hematologic malignancies. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in Biosynergy (AC101), a preclinical project. It has operations in the United States, Sweden, Asia, and internationally. The company has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a license agreement with Janssen Biotech, Inc. for developing ADC-1013. Alligator Bioscience AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.